New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...

AxoGen’s latest earnings call struck an optimistic tone, as management balanced strong revenue growth, a landmark FDA approval and a fortified balance sheet against temporary margin and cost pressures ...

An update from Profound Medical ( (TSE:PRN) ) is now available.